1. Home
  2. RIVN vs UTHR Comparison

RIVN vs UTHR Comparison

Compare RIVN & UTHR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rivian Automotive Inc.

RIVN

Rivian Automotive Inc.

HOLD

Current Price

$14.87

Market Cap

23.1B

ML Signal

HOLD

Logo United Therapeutics Corporation

UTHR

United Therapeutics Corporation

HOLD

Current Price

$535.53

Market Cap

23.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RIVN
UTHR
Founded
2009
1996
Country
United States
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
23.1B
23.9B
IPO Year
2021
1999

Fundamental Metrics

Financial Performance
Metric
RIVN
UTHR
Price
$14.87
$535.53
Analyst Decision
Buy
Buy
Analyst Count
21
14
Target Price
$17.89
$531.79
AVG Volume (30 Days)
26.2M
466.2K
Earning Date
01-01-0001
05-28-2026
Dividend Yield
N/A
N/A
EPS Growth
34.54
13.07
EPS
N/A
27.86
Revenue
$5,387,000,000.00
$1,483,300,000.00
Revenue This Year
$33.90
$7.77
Revenue Next Year
$63.73
$11.11
P/E Ratio
N/A
$19.12
Revenue Growth
8.39
2.38
52 Week Low
$10.36
$266.98
52 Week High
$22.69
$548.12

Technical Indicators

Market Signals
Indicator
RIVN
UTHR
Relative Strength Index (RSI) 44.19 62.29
Support Level $14.62 $464.92
Resistance Level $16.17 N/A
Average True Range (ATR) 0.74 19.31
MACD 0.07 4.83
Stochastic Oscillator 11.77 88.41

Price Performance

Historical Comparison
RIVN
UTHR

About RIVN Rivian Automotive Inc.

Rivian is a battery electric vehicle automaker that sells its vehicles in the US and Canada. The company also develops electronic control units and related software for autos in a joint venture with Volkswagen. Rivian has multiple vehicles in its fleet, which include a luxury truck and full-size SUV and a delivery van. The company also plans to begin selling a midsize SUV in 2026. Total deliveries were nearly 52,000 in 2024. Rivian is also developing autonomous driving software to be used in its vehicles.

About UTHR United Therapeutics Corporation

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

Share on Social Networks: